Trinity Biotech EBITDA 2010-2025 | TRIB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Trinity Biotech ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Trinity Biotech ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$230.8B
Boston Scientific (BSX)	$157.3B
Stryker (SYK)	$150.7B
EssilorLuxottica (ESLOY)	$147.8B
Medtronic (MDT)	$118.8B
Lonza Group Ag (LZAGY)	$49.6B
Haleon (HLN)	$44B
ResMed (RMD)	$43B
Agilent Technologies (A)	$34.6B
GE HealthCare Technologies (GEHC)	$34.3B
Terumo (TRUMY)	$27.7B
Koninklijke Philips (PHG)	$27.3B
Insulet (PODD)	$23.3B
Zimmer Biomet Holdings (ZBH)	$21.3B
Smith & Nephew SNATS (SNN)	$16.4B
Baxter (BAX)	$12.6B
Sunny Optical Technology (SNPTF)	$10.8B
Bio-Rad Laboratories (BIO)	$8.2B
Demant (WILYY)	$8.1B
Lantheus Holdings (LNTH)	$4B
Envista Holdings (NVST)	$3.6B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Perrigo (PRGO)	$3.4B
Prestige Consumer Healthcare (PBH)	$3.3B
ICU Medical (ICUI)	$3.2B
Haemonetics (HAE)	$2.7B
LeMaitre Vascular (LMAT)	$2.3B
Acuren (TIC)	$2.1B
QuidelOrtho (QDEL)	$1.9B
Curaleaf Holdings (CURLF)	$1.9B